@article {Nederpelt:2021:0090-3493:e1025,
title = "Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis",
journal = "Critical Care Medicine",
parent_itemid = "infobike://wk/ccm",
publishercode ="wk",
year = "2021",
volume = "49",
number = "10",
publication date ="2021-06-24T00:00:00",
pages = "e1025-e1036",
itemtype = "ARTICLE",
issn = "0090-3493",
eissn = "1530-0293",
url = "https://www.ingentaconnect.com/content/wk/ccm/2021/00000049/00000010/art00013",
doi = "doi:10.1097/CCM.0000000000005059",
keyword = "hemorrhage, factor Xa inhibitors, andexanet alfa, prothrombin complex concentrate, anticoagulation reversal",
author = "Nederpelt, Charlie J. and Naar, Leon and Krijnen, Pieta and le Cessie, Saskia and Kaafarani, Haytham M. A. and Huisman, Menno V. and Velmahos, George C. and Schipper, Inger B.",
abstract = "
OBJECTIVES:
To combine evidence on andexanet alfa and prothrombin complex concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal strategies. 
DATA SOURCES:
Embase, Pubmed, Web of Science, and the Cochrane Library. 
STUDY SELECTION:
Observational studies and randomized clinical trials studying hemostatic effectiveness of andexanet alfa or prothrombin complex concentrate for acute reversal of factor Xa inhibitor-associated hemorrhage. 
DATA EXTRACTION:
Two independent reviewers
extracted the data from the studies. Visualization and comparison of hemostatic effectiveness using Sarode et al or International Society of Thrombosis and Hemostasis Scientific and Standardization Committee criteria at 12 and 24 hours, (venous) thrombotic event rates, and inhospital mortality
were performed by constructing Forest plots. Exploratory analysis using a logistic mixed model analysis was performed to identify factors associated with effectiveness and venous thromboembolic event. 
DATA SYNTHESIS:
A total of 21 studies were included (andexanet: 438 patients;
prothrombin complex concentrate: 1,278 patients). The (weighted) mean effectiveness for andexanet alfa was 82% at 12 hours and 71% at 24 hours. The (weighted) mean effectiveness for prothrombin complex concentrate was 88% at 12 hours and 76% at 24 hours. The mean 30-day symptomatic venous
thromboembolic event rates were 5.0% for andexanet alfa and 1.9% for prothrombin complex concentrate. The mean 30-day total thrombotic event rates for andexanet alfa and prothrombin complex concentrate were 10.7% and 3.1%, respectively. Mean inhospital mortality was 23.3% for andexanet versus
15.8% for prothrombin complex concentrate. Exploratory analysis controlling for potential confounders did not demonstrate significant differences between both reversal agents. 
CONCLUSIONS:
Currently, available evidence does not unequivocally support the clinical effectiveness
of andexanet alfa or prothrombin complex concentrate to reverse factor Xa inhibitor-associated acute major bleeding, nor does it permit conventional meta-analysis of potential superiority. Neither reversal agent was significantly associated with increased effectiveness or a higher rate of
venous thromboembolic event. These results underscore the importance of randomized controlled trials comparing the two reversal agents and may provide guidance in designing institutional guidelines.",
}